(Q40521084)

English

Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene

scientific article published on September 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Tulin Budak-Alpdogan

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Onder Alpdogan

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Debabrata Banerjee

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Eunice Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Malcolm A S Moore

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Joseph R Bertino

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

574-584

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Stem cell transplantation and gene therapy for HIV-related lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Drug resistance gene transfer: Stem cell protection and therapeutic efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Marrow protection - transduction of hematopoietic cells with drug resistance genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Effects of the negative control region on expression from retroviral LTR

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Retroviral Transduction of a Mutant Dihydrofolate Reductase-Thymidylate Synthase Fusion Gene into Murine Marrow Cells Confers Resistance to Both Methotrexate and 5-Fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.115

7 January 2021

Identifiers

10.1016/J.YMTHE.2004.06.115

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40521084&oldid=1899855316"